Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05868876 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Start date: June 29, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ia/Ib open label,clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors

NCT ID: NCT05868629 Recruiting - Clinical trials for Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Start date: February 6, 2024
Phase:
Study type: Observational

This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.

NCT ID: NCT05868174 Recruiting - Clinical trials for Advanced Solid Tumor

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.

NCT ID: NCT05867563 Recruiting - Clinical trials for Advanced Malignant Neoplasm

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Start date: July 4, 2023
Phase: Phase 1
Study type: Interventional

TQB2103 injection is an antibody-drug conjugate (ADC) targeting claudin (CLDN) 18.2. This study aimed to evaluate the safety and tolerability, pharmacokinetic characteristics and immunogenicity of TQB2103 injection in patients with advanced malignant tumors as well as its initial effectiveness.

NCT ID: NCT05867420 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Start date: August 3, 2023
Phase: Phase 1
Study type: Interventional

The study is a Phase 1dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent in patients with selected advanced solid tumors.

NCT ID: NCT05867251 Recruiting - Clinical trials for Advanced Solid Tumor

Study of AVZO-021 in Patients With Advanced Solid Tumors

Start date: August 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

NCT ID: NCT05867186 Recruiting - Pediatric Oncology Clinical Trials

Fit to Fight Childhood Cancer

Kolibri
Start date: June 20, 2023
Phase:
Study type: Observational

The aim of the study is to investigate the influence of exercise on physical performance and psychosocial aspects in children and adolescents with cancer during and after treatment.

NCT ID: NCT05866692 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: August 17, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.

NCT ID: NCT05865964 Recruiting - Surgery Clinical Trials

Anthropological, Socio-cultural and Psychological Surgeons' Factors in Oncology and Brakes for Evaluation of Innovations

SURGprofil
Start date: December 14, 2022
Phase:
Study type: Observational

The field of surgery continues to benefit from innovative solutions, changing surgical methods and techniques. Evaluation in terms of efficacy and Quality-Safety is an essential topic that directly affects the introduction of innovations. It is essential to carry out a robust evaluation strategy for surgical innovations, even if these are often opposed to drug innovations. The aim of this study is to investigate the anthropological, socio-cultural and psychological differences of surgeons that influence the evaluation of surgical innovations.

NCT ID: NCT05865002 Recruiting - Clinical trials for Relapsed Malignant Solid Neoplasm

A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

Start date: September 5, 2023
Phase: Phase 1
Study type: Interventional

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.